Clinical Trials Browser

Phase 2 × Central Nervous System Neoplasms × cabozantinib × Clear all

NCT05425004 2026-03-05

Cabozantinib for Patients With Recurrent or Progressive Meningioma

Phase 2 Recruiting

Meningioma, Central Nervous System Neoplasms